In a landmark project, Integritas had the privilege of supporting the US affiliate of an international firm with their inaugural direct entry into the U.S. pharmaceutical market. This venture marked a significant milestone for our client, as they embarked on their first direct foray into the highly competitive U.S. pharmaceutical landscape.
The challenge at hand was monumental—our client was preparing for a high-stakes, one-shot phase 3 clinical trial. This trial was not only expensive but also represented a critical turning point in their journey. The success of this endeavor hinged on the precise design of the trial, a task that demanded unparalleled expertise and precision.
To navigate this complex terrain successfully, Integritas embarked on a comprehensive journey of discovery. We initiated qualitative research, engaging with key stakeholders who held the power to shape the trial's fate. These stakeholders included medical specialists, healthcare practitioners, and insurers (payors), each playing a vital role in the healthcare ecosystem.
Armed with invaluable insights from these qualitative engagements, we set out to design a conjoint research study that would serve as the cornerstone of our strategy. The primary objective was to ensure that the phase 3 trial's primary and secondary endpoints seamlessly aligned with the expectations of the medical community.
This project was a testament to our ability to provide critical insights that transcend industry boundaries. By harnessing the power of qualitative research and conjoint analysis, we not only guided our client through the uncharted waters of their first direct U.S. pharmaceutical launch, but also set the stage for a future defined by innovation and success.
At Integritas, we don't merely support our clients; we empower them to shape the future of healthcare through strategic decision-making and unwavering dedication to excellence